
On this page
Published:
Key Takeaways
- A cellular or out-of-band connection changes the network path, not the need for authorization and product risk assessment.
- Device service access should have defined identities, privileges, approval, logging, and revocation behavior.
- Remote security testing needs its own scope and clinical safeguards; maintenance permission does not authorize attack testing.
- Architecture views, threat modeling, SBOM scope, and postmarket planning answer different access-path questions.
- The manufacturer owns product design and release decisions; the hospital owns local access approval and clinical operating decisions.
Medical device remote access security requires an authorized user, an approved purpose, limited privileges, and a way to observe and stop the connection. Document every service and testing path, including cellular links and cloud relays. Assess whether access can change treatment settings, software, or patient information. A connection outside the hospital network still reaches the product and needs review. Manufacturer product controls, hospital authorization, and penetration-test safeguards are separate responsibilities.
A support connection can shorten maintenance work. It can also bypass the route that a hospital normally uses to control access to clinical equipment. The important distinction is what the connection can do, not what the supplier calls it.
Medical device remote access security covers service laptops, cloud management channels, remote desktop tools, gateways, and temporary testing connections. Some access paths are part of the shipped product. Others exist only in a controlled lab.
The FDA's Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions recommends assessing the connected system and communicating secure operating conditions. HHS guidance addresses the organization's access and supplier practices.
A useful review connects both. It identifies the person using the path, the device functions reachable through it, and the controls that remain in force when something fails. It also distinguishes actual evidence from claims about a particular remote-access technology.
Why This Matters
Remote access crosses organizational and technical boundaries. A manufacturer may operate the service platform while a hospital operates the device and a contractor holds the service credentials. The connection needs a clear owner at each boundary.
HHS's 2023 HICP Technical Volume 1 describes 10 cybersecurity practices for small healthcare organizations. Access management, asset management, network management, and incident response are among the practices relevant to supplier connections. This sourced practice count does not measure the effectiveness of any particular access tool.
The FDA's Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions, February 3, 2026, recommends lifecycle security evidence and system-level assessment. A manufacturer should not omit a service infrastructure dependency simply because a hospital does not manage it.
IEC 81001-5-1 supports security activities for health software. IEC 80001-1 addresses risk management for connected health IT systems, while ISO 14971 addresses device safety risk management. These references support different parts of the assessment; they do not certify a remote connection.
The clinical consequence must remain explicit. A session that only reads diagnostic logs has a different impact from one that changes an alarm setting or installs firmware. Patient-safety severity requires manufacturer clinical context rather than a generic remote-access score.
What Belongs in the Remote Access Inventory?
Record every path that can reach the product or its supporting service, including paths intended only for installation and maintenance. Start with the shipped configuration and identify temporary arrangements separately.
Include the connection origin, destination, protocol, authentication system, approval owner, and permitted actions. Record whether the session reaches an operating system, application interface, service processor, or update mechanism.
List dependencies such as a cloud relay, jump host, identity provider, service agent, or local gateway. Explain whether those dependencies are manufacturer-managed, hospital-managed, or operated by another supplier.
| Path | Question to resolve | Evidence |
|---|---|---|
| Remote desktop | Can the user change device configuration? | Roles, approval procedure, and access tests |
| Cloud service channel | Who can issue commands to a specific device? | Device identity and authorization design |
| Cellular gateway | What can the gateway reach besides its target? | Connection diagram and enforced boundaries |
| Service laptop | Which accounts and tools remain after service? | Maintenance procedure and cleanup record |
| Remote test connection | Is the equipment outside clinical operation? | Signed scope and stop/recovery plan |
A diagram should show the actual path. Calling a system secure or isolated without recording its reachable interfaces leaves the main question unanswered.
Does Out-of-Band Access Remove Hospital Security Risk?
No. Out-of-band access may avoid the hospital's primary network, but it still connects an external party to the device or test equipment. Its risks depend on the reachable functions and enforced boundaries.
A cellular gateway may reduce the need for a firewall change. It can also create a path the hospital cannot observe through its normal controls. Review device access, gateway management, provider accounts, update channels, and disconnection behavior.
Do not assume that a gateway has no access to patient information because the connection is described as a service channel. Identify what logs, files, commands, and memory are exposed and how that access is restricted.
Network independence is not clinical authorization. An external connection needs approval, an agreed purpose, a defined equipment state, and a reviewed impact boundary even when it bypasses the hospital LAN.
A lab test connection and a deployed hospital service path also need separate records. The manufacturer should explain whether the temporary connection is removed before release and whether any agents or credentials remain on the product.
Which Identity and Privilege Controls Should Be Reviewed?
Review whether each session can be attributed to an authorized person and limited to the intended task. Named accounts, multifactor authentication where supported, and scoped permissions are practical review points.
Separate reading logs, changing configuration, installing updates, and accessing patient data. Do not grant broad administrator privileges just because a maintenance workflow is easier to run that way.
Define how access is requested, approved, activated, expired, and revoked. Include supplier staff changes and emergency access. The process should identify the person who can disable a session while the product continues operating safely.
Test negative cases in an appropriate environment. What happens when approval expires? Can an account for one customer reach another customer's device? Does a read-only role block configuration changes on the server as well as in the interface?
HHS's Cybersecurity Performance Goals include multifactor authentication and supplier-related practices. These are voluntary goals, not a claim that one authentication method is a universal FDA legal requirement for every interface.
How Should the Threat Model and Architecture Views Describe Access?
The threat model should connect the access path to reachable assets, misuse scenarios, controls, and evidence. It should remain separate from architecture diagrams and from scoring decisions.
For example, an illustrative service workflow may allow a technician to retrieve logs through a cloud relay. Assess credential theft, unauthorized command requests, cross-customer access, and disclosure through exported logs. These are review scenarios, not findings attributed to an actual client.
See also: Cybersecurity for Small Hospitals: Protecting Connected Medical Devices in 2026, and Cybersecurity for Genomic Sequencing and Diagnostic Systems.
The Global System view places the device and supporting services in context. The Multi-Patient Harm view considers whether shared service infrastructure could affect several deployed devices. The Updateability/Patchability view describes authorized maintenance and software change paths.
The Security Use Case view describes relevant access behavior and boundaries. The views should be consistent with the product configuration and the manufacturer's current evidence; a label on a drawing does not prove that the control is enforced.
Security impact and safety harm are different assessments. A compromised account may permit configuration changes, but the resulting patient consequence depends on device behavior and clinical safeguards. Use manufacturer-supplied harm context, not an invented safety severity.
Our medical device threat modeling service addresses that analysis. Architecture views remain separate deliverables rather than a substitute name for the threat model.
What Makes Remote Penetration Testing Different from Remote Service?
Remote penetration testing deliberately exercises security behavior within an agreed scope. Routine maintenance access does not authorize those actions or establish that the equipment is suitable for testing.
Define the device model, release, interfaces, supporting services, credentials, and physical setup. Agree on what the tester may change, how disruptive tests are controlled, who can stop the work, and how the environment is restored.
A remote channel cannot reproduce every physical condition. Identify which interfaces are available and which require local support or shipped hardware. If an interface is outside the test setup, report the limitation instead of claiming complete coverage.
Distinguish test observations from broader conclusions. A failed exploit attempt may show that a specific technique did not work under the tested conditions. It does not establish that the vulnerability is absent or that every attack path has been covered.
Testing should avoid equipment treating patients and use an appropriate authorized environment. Clinical engineering, the manufacturer, and the test team should coordinate any setup that could affect connected clinical services.
Review medical device penetration testing scope before selecting a remote delivery method. The scope and evidence matter more than whether the access path is called a platform, appliance, or service.
How Do SBOM and Postmarket Plans Cover the Service Path?
Component records and postmarket procedures should cover the supporting software that belongs within the product system's defined scope. A device-only component list may miss a manufacturer-operated service dependency.
Identify service agents, gateways, update clients, relay components, and relevant supporting applications. State which release each record describes and where its coverage stops. Do not imply that the manufacturer knows every component in a hospital's separately managed network.
When a component vulnerability appears, determine whether the affected version is present and reachable through the service path. An SBOM match starts that assessment; it does not finish the exploitability or patient-safety analysis.
Plan for stolen credentials, compromised service infrastructure, and customer notification. Define who investigates, who can revoke access, and how product support continues if the remote channel is unavailable.
Section 524B includes vulnerability monitoring, coordinated disclosure, and update/patch duties for covered cyber-device submissions. Hospital access approval is not a substitute for those manufacturer processes. Our postmarket cybersecurity support keeps those responsibilities visible in the product program.
How Blue Goat Cyber Approaches This
Blue Goat reviews remote access as part of the medical device's connected system. We separate product design, hospital operating decisions, and the arrangements needed to conduct security testing.
We use architecture information, interface descriptions, service procedures, and the relevant software release to define the security scope. Threat modeling identifies misuse paths and control assumptions. Penetration testing examines security behavior and records observed conditions and limitations rather than presenting a delivery technology as proof of coverage.
The manufacturer supplies clinical context and owns patient-harm severity, risk acceptance, verification and validation, and release approval. A hospital controls its own access permissions and clinical operating procedures. Those decisions are not reassigned to a tester because the work occurs remotely.
For manufacturer engagements, we connect findings to remediation evidence and retesting. Our medical device cybersecurity consulting can help connect those records to premarket documentation and lifecycle processes. If the FDA raises a cybersecurity question, we answer it at no extra cost until the cybersecurity portion is closed.
Frequently Asked Questions
What is medical device remote access security?
It is the set of product controls and operating procedures that restrict external access to a medical device and its supporting services. The review identifies users, permissions, approval, session records, revocation, and clinical effects. It includes supplier maintenance, cloud command channels, and temporary test connections. Manufacturer design responsibilities, hospital access decisions, and testing permissions remain separate even when they use the same technology.
Is a cellular service connection safer than a hospital network connection?
It depends on the architecture and controls. A cellular connection may avoid exposure through part of the hospital network, but it creates another path to the device or gateway. Review identity, reachable functions, management access, logging, and failure behavior. Do not assume that an out-of-band label prevents patient data access or removes the need for hospital authorization and clinical coordination.
Can manufacturers use one administrator account for all customers?
A shared administrator account makes attribution, revocation, and customer separation harder. Review whether named identities, scoped privileges, and device-specific authorization can support the service workflow. Test that one customer's access cannot reach another customer's device. The exact design depends on the product, but broad privileges should be justified and assessed rather than accepted as a convenience without supporting control evidence.
Does remote testing cover every physical device interface?
No delivery method establishes interface coverage by itself. A remote setup may expose Ethernet or a service interface but not a physical debug port, radio condition, or local user workflow. The test scope should list what is accessible, how local support is provided, and what remains untested. Report those limitations alongside the findings instead of treating remote access as complete device coverage.
Does the FDA require every service connection to use the same controls?
No single universal connection checklist replaces device-specific assessment. The FDA's guidance recommends cybersecurity design and evidence appropriate to the device and connected system; Section 524B adds statutory duties for covered cyber devices. Assess the access path, intended use, clinical consequences, and supporting controls. HHS's voluntary healthcare goals are useful references, but they are not themselves a mandatory FDA interface specification.
CTA
Planning remote service or security testing for a medical device? Discuss the device and test scope, including its release, interfaces, service dependencies, and clinical constraints. If the FDA raises a cybersecurity question, we answer it at no extra cost until the cybersecurity portion is closed.
About the author

Christian Espinosa, MBA · Founder & CEO, Blue Goat Cyber
U.S. Air Force Academy graduate and veteran with 30+ years in cybersecurity. Founded Alpine Security in 2014 (acquired 2020), then Blue Goat Cyber in 2022. Blue Goat track record: 275+ FDA submissions supported, zero cybersecurity rejections. Author of three books including The Smartest Person in the Room. Ironman triathlete and mountaineer.
Sources & references
Primary sources cited in this article. Links open in a new tab.
